Professor Detlev Ploog On March 19-21, 1989, a symposium entitled "Integrative Biological Psychiatry" was held at the Ringberg Castle (Bavaria) to honor the scientific work of Detlev Ploog, who retired at that time from his position as the Director of the Max Planck Institute of Psychiatry in Munich. The lectures represent an overview of the scientific work conducted at the Max Planck Institute within the recent past and thus also reflect the scientific intentions and research strategies of Detlev Ploog, who brought together extremely divergent tendencies within basic and clinical research and integrated the findings to elucidate new perspectives for fundamental psychiatric problems. His ability to combine topics such as brain and behavior with neuropsychological, neuroethological, psychopharmacological, and behavioral aspects generated a scientific climate in which psychiatric research flourished. The chapters in the present volume represent a documentation of this integrative view on psychiatry, and we, who worked together with Detlev Ploog as his university colleagues at the Ludwig Maximilians University (H. H. ), the Technical University of Munich (H. L. ) and as his successor at the Max Planck Institute (F. H. ) wish him, also after his retirement, continued scientific success, with many additional contributions to modern psychiatry. Hanns Hippius Florian Holsboer Hans Lauter Preface One of the main purposes of science is to elaborate models of natural processes that should be as realistic as possible.

First multi-year cumulation covers six years: 1965-70.

This volume is a major international compilation in the field of social psychiatry. Building upon the work of John Wing, director of the Social Psychiatry Unit of the Medical Research Council in Great Britain, these essays make up a series of variations on one of the basic themes of human existence--the interaction between people and their environment. The authors are concerned with social psychiatry; their attention is focused on those aspects of the environment that affect psychological states, whether of persons previously healthy or already suffering from some form of psychiatric illness or disability. Social relationships and psychiatric disturbances are murky ground for investigators, many of whom have become lost or returned with nothing but truisms or unvalidated assertions. In this collection, the editor has brought together leading international researchers in the field who combined a primary emphasis on theory and methodology with an equal regard for direct observation and practice and a scrupulous attention to detail. Insistence on the most accurate measurement possible is the natural consequence of an adherence to clear theoretical positions, which both informs and demands such an approach. This book springs from the work of the Medical Research Council's Social Psychiatric Unit, but because of the breadth of the Unit's concerns over the years, it is also a comprehensive work in the field of social psychiatry. It draws contributions from the leading international figures and will be a landmark work for professionals in social and clinical psychiatry, as well as for anyone with an interest in the social aspects of mental health.

Affective disorders are a subject of interest to clinicians for more than a century. The awareness of an urgent need for an evidence-based “personalized” approach of treatment is growing in the field of psychiatry. This book brings together leading experts to create a volume of equal interest and usefulness to students, clinicians and researchers alike, which should serve as common knowledge. Specific themes of major depression, bipolar disorder, and schizoaffective disorder are critically reviewed, addressing topics such as neurobiological mechanisms underlying the pathogenesis, treatment resistant depression, translational research and challenging stigma of serious mental illness. Particular emphasis is put on novel developments in Cognitive-Behavioral Therapy and on attention to causal mechanisms of behaviour change in the Cognitive Behavioral Analysis System of Psychotherapy.

Authored by over 500 internationally acclaimed expert editors and chapter authors from around the world. Completely updated and expanded with almost 40 new chapters. Significantly increased attention to the role of culture in all aspects of evaluation and care. New sections on Digital Mental Health Services and Technologies, Treatment Issues in Specific Populations and Settings, and on Prevention, Systems of Care, and Psychosocial Aspects of Treatment address key advances. This edition is the first comprehensive reference work to cover the entire field of psychiatry in an updateable format, ensuring access to state of the art information. Earlier editions were called “the best current textbook of psychiatry” by the New England Journal of Medicine, and “the gold standard” by the American Journal of Psychiatry. Tasman’s Psychiatry, 5th Edition, builds on the initial vision in prior editions of approaching psychiatric evaluation and care from an integrative bio-psycho-social-cultural perspective. It is designed to be an essential and accessible reference for readers at any level of experience. This editorial approach encompasses the importance of the first encounter between patient and clinician, followed by the complex task of beginning to develop a therapeutic relationship and to develop and implement a treatment plan in collaboration with the patient. The importance of increasing attention to the role of culture and social determinants of mental health is reflected both in specific chapters and in components of many chapters throughout the book, especially in those pertaining to clinical evaluation, the therapeutic alliance, and treatment. The global scope of this edition is reflected throughout the book, including the section on psychiatric disorders where evaluation using both ICD 11 and DSM 5-TR is discussed. Most chapters are authored by experts from at least two different countries or continents, adding a critically important dimension which often is missing in major psychiatric textbooks. Tasman’s Psychiatry, 5th Edition, is an essential reference for all medical professionals and students who need a trusted reference or learning tool for psychiatry, psychology, clinical research, social work, counseling, therapy, and all others.

Qualitative evaluations of buccal smear specimens have indicated an unusually high incidence of triple-X females in a hospitalized schizo phrenic population. Specimens from adult prisoners have also indicated an unusually high incidence of triple-X females. Studies of a population of confined juvenile offenders, on the other hand, have indicated an unusually high incidence of one-X females. No unusual indications were observed in a population of "normal" volunteer females. The data and their implications are discussed in context with previous observations. ACKNOWLEDGMENTS This study was made possible primarily by research grants from the Scottish Rite Committee on Research in Schizophrenia, The National Association for Mental Health, Inc. Additional support was provided by a grant from the National Institutes of Health, GRS-05563. The study has been supported by the State of Ohio, Department of Mental Hygiene and Correction, Division of Mental Hygiene. The author is particularly indebted to Edward N. Hinko, M.D., Regional Director of Research, whose advice and help made the present study possible. Invaluable cooperation and help have been received from the following administrators and their staffs: F. A. Lingl, M.D. (Cleve land Psychiatric Institute); Martha Wheeler (Ohio Reformatory for Women); M. B. McLane (Scioto Village); M. B. Holmes, M. D., and S. Caruso, M. D. (Massillon State Hospital); G. F. Ogram, M. D. (Athens State Hospital); C. Waltner, M. D. (Woodside Receiving Hospital); A. Mako, M. D. (Fairhill Psychiatric Hospital); and W. G. Stover, M. D.

Overexpression of receptor tyrosine kinases (RTKs) has been implicated in cancer. Increasing evidence suggests that dysregulation of RTKs is reported in many neurodegenerative and psychiatric disorders. Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders provides a fundamental, pragmatic map of RTKs structure, activation, functions, mechanism of action, gene regulation, and signaling pathways in developing central nervous system (CNS), adult normal CNS, neurodegenerative and psychiatric disorders. Additionally, the structure, function, activation, and therapeutic potential of many growth factors have been covered. Here, international experts in the field offer a comprehensive discussion of results of pre-clinical and clinical studies of repositioning of anti-cancer receptor tyrosine kinase inhibitors (RTKIs) and other promising protein kinase inhibitors in various neurodegenerative disorders including, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington's disease, and multiple sclerosis, and psychiatric disorders including, anxiety, depression, alcohol use disorder, and schizophrenia. In addition, the book discusses the obstacles and opportunities for the potential repositioning of kinase inhibitors in neurodegenerative and psychiatric disorders. Provides a thorough overview of RTKs biology and their role in health and disease progression and modulation Highlights RTK families and the numerous receptors within each subfamily Examines RTKIs and other protein kinase inhibitors in pre-clinical and clinical trials in both neurodegenerative and psychiatric disorders Gives future directions of possible safe effective targeted RTKIs and other protein kinase inhibitors that may be repositioned in various neurodegenerative and psychiatric disorders Includes chapter contributions from renowned experts in biology, pharmacology, neurology, psychiatry, and oncology

An award-winning sociologist unearths how a group of ordinary people debilitated by excruciating pain developed their own medicine from home-grown psilocybin mushrooms—crafting near-clinical grade dosing protocols--and fought for recognition in a broken medical system. Cluster headache, a diagnosis sometimes referred to as a ‘suicide headache,’ is widely considered the most severe pain disorder that humans experience. There is no cure, and little funding available for research into developing treatments. When Joanna Kempner met Bob Wold in 2012, she was introduced to a world beyond most people's comprehension—a clandestine network determined to find relief using magic mushrooms. These ‘Clusterbusters,’ a group united only by the internet and a desire to survive, decided to do the research that medicine left unfinished. They produced their own psychedelic treatment protocols and managed to get academics at Harvard and Yale to test their results. Along the way, Kempner explores not only the fascinating history and exploding popularity of psychedelic science, but also a regulatory system so repressive that the sick are forced to find their own homegrown remedies, and corporate America and university professors stand to profit from their transgressions. From the windswept shores of the North Sea through the verdant jungle of Peruvian Amazon to a kitschy underground palace built in a missile silo in Kansas, Psychedelic Outlaws chronicles the rise of psychedelic medicine amid a healthcare system in turmoil. Kempner’s gripping tale of community and resilience brings readers on a eye-opening journey through the politics of pain, through the stories of people desperate enough to defy the law for a moment of relief.